- Report
- February 2024
- 107 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- November 2023
- 89 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- June 2023
- 101 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- June 2023
- 89 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- October 2023
- 146 Pages
Global
From €3367EUR$3,528USD£2,821GBP
€3961EUR$4,150USD£3,318GBP
- Report
- October 2022
- 251 Pages
Global
From €3407EUR$3,570USD£2,855GBP
- Report
- November 2023
- 285 Pages
Global
From €3407EUR$3,570USD£2,855GBP
- Report
- March 2022
- 264 Pages
Global
From €3543EUR$3,712USD£2,968GBP
- Book
- December 2019
- 400 Pages
- Book
- July 2023
- 512 Pages
- Book
- July 2023
- 512 Pages
- Book
- September 2009
- 416 Pages
- Book
- June 2019
- 336 Pages

High Content Screening (HCS) is a biotechnology technique used to analyze and quantify the effects of drugs, chemicals, and genetic modifications on cells. It is a powerful tool for drug discovery and development, as well as for basic research. HCS combines automated microscopy, image analysis, and data management to provide a comprehensive view of cellular responses. It can be used to measure a variety of cellular parameters, including cell morphology, protein expression, and gene expression.
HCS is used in a variety of applications, including drug discovery, toxicity testing, and stem cell research. It is also used to study the effects of environmental factors on cells, such as temperature, pH, and light. HCS is becoming increasingly important in the biotechnology industry, as it allows researchers to quickly and accurately analyze large amounts of data.
Some companies in the HCS market include Thermo Fisher Scientific, PerkinElmer, GE Healthcare, BioTek Instruments, and Olympus. Show Less Read more